Related Experiment Video

Updated: Jun 22, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets

Kim N Chi1, Anders Bjartell, David Dearnaley

  • 1BC Cancer Agency, Vancouver, British Columbia, Canada. kchi@bccancer.bc.ca

European Urology
|June 30, 2009
PubMed
Abstract

Insights

New targeted therapies are emerging for castration-resistant prostate cancer (CRPC), offering hope for patients with limited options. These agents target various molecular pathways driving cancer progression, with many in late-stage clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Castration-resistant prostate cancer (CRPC) presents a significant clinical challenge due to limited standard treatment options.
  • Understanding the molecular underpinnings of prostate cancer (PCa) progression is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To review the concepts and rationale behind targeted agents in late-stage clinical testing for CRPC.
  • To provide an overview of emerging therapies for advanced prostate cancer.

Main Methods:

  • Systematic literature search of MEDLINE (1996-2009) and clinical trial registries.
  • Hand-searching bibliographies of retrieved articles and conference abstracts.
  • Identification of novel targeted therapies in phase 3 trials for CRPC.

Main Results:

  • Advances in understanding PCa molecular mechanisms have led to diverse targeted treatment approaches.
  • Agents targeting androgen receptor (AR) activation, angiogenesis, immunotherapy, and other pathways are in late-stage trials.
  • Multiple novel agents show early promise for CRPC treatment.

Conclusions:

  • Several new agents targeting PCa progression mechanisms are in clinical trials.
  • These targeted therapies demonstrate promising early results for CRPC.
  • Novel treatment options for CRPC are anticipated in the near future.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...